ALK rearrangement testing by FISH analysis in non-small-cell lung cancer patients: Results of the first italian external quality assurance scheme

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1470-1476

  Marchetti, Antonio ^a   Barberis, Massimo ^b   Papotti, Mauro ^c   Rossi, Giulio ^d   Franco, Renato ^e   Malatesta, Sara ^a   Buttitta, Fiamma ^a   Ardizzoni, Andrea ^f   Crinò, Lucio ^g   Gridelli, Cesare ^h   Taddei, Gian Luigi ⁱ   Clemente, Claudio ^j   Scagliotti, Giorgio ^c   Normanno, Nicola ^e   Pino, Carmine ^k  

^a UNIVERSITY OF CHIETI   (Italy)

^b EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY HOSPITAL OF PARMA   (Italy)

^g Perugia Hospital   (Italy)

^h S G MOSCATI HOSPITAL   (Italy)

ⁱ UNIVERSITY OF FLORENCE   (Italy)

^j IRCCS POLICLINICO SAN DONATO   (Italy)

^k UNIVERSITY OF BOLOGNA   (Italy)

more..

Author keywords

ALK rearrangement; FISH; Non small cell lung cancer; Quality assessment

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER PATIENT; CANCER TISSUE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC ERROR; DIAGNOSTIC TEST ACCURACY STUDY; FALSE POSITIVE RESULT; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; GENETIC ANALYSIS; GENOTYPE; HUMAN; HUMAN TISSUE; LABORATORY; MAJOR CLINICAL STUDY; MOLECULAR PATHOLOGY; MULTICENTER STUDY; NON SMALL CELL LUNG CANCER; PATIENT REFERRAL; PREDICTIVE VALUE; PRIORITY JOURNAL; QUALITY CONTROL; SCORING SYSTEM; TASK PERFORMANCE; TISSUE MICROARRAY; TISSUE SECTION; CLINICAL TRIAL; ENZYMOLOGY; GENETICS; LUNG TUMOR; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; STANDARDS;

CARCINOMA, NON-SMALL-CELL LUNG; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; QUALITY CONTROL; RECEPTOR PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; TISSUE ARRAY ANALYSIS;

EID: 84925804527     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000280     Document Type: Article

References (21)

1. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
3. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004;101:13306-13311.
4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
5. Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994;263:1281-1284.
6. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
7. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
8. Choi YL, Takeuchi K, Soda M, et al. Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 2008;68:4971-4976.
9. Takeuchi K, Choi YL, Soda M, et al. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 2008;14:6618-6624.
10. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
11. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
12. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
13. Camidge DR, Bang Y, Kwak EL, et al. Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC). J Clin Oncol 2011;29(suppl):abst 2501.
14. Crinò L, Kim D, Riely GJ, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011;29(suppl):abst 7514.
15. Xalkori (crizotinib): EPAR (European public assessment report) - Summary for the public. [EMA Web site]. First published November 14, 2012. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002489/human-med-001592.jsp&mid=WC0b01ac058001d124. Accessed July 19, 2014.
16. FDA NEWS RELEASE. FDA approves Xalkori with companion diagnostic for a type of late-stage lung cancer. [FDA Web site]. August 26, 2011. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm269856.htm. Accessed July 19, 2014.
17. Marchetti A, Ardizzoni A, Papotti M, et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013;8:352-358.
18. van Krieken JH, Normanno N, Blackhall F, et al. Guideline on the requirements of external quality assessment programs in molecular pathology. Virchows Arch 2013;462:27-37.
19. Thunnissen E, Bovée JV, Bruinsma H, et al. EGFR and KRAS quality assurance schemes in pathology: generating normative data for molecular predictive marker analysis in targeted therapy. J Clin Pathol 2011;64:884-892.
20. Normanno N, Pinto C, Castiglione F, et al. KRAS mutations testing in colorectal carcinoma patients in Italy: from guidelines to external quality assessment. PLoS One 2011;6:e29146.
21. Normanno N, Pinto C, Taddei G, et al. Results of the First Italian External Quality Assurance Scheme for somatic EGFR mutation testing in non-small-cell lung cancer. J Thorac Oncol 2013;8:773-778.